Pharmafile Logo
Pharmafocus logo
Advanced Search

chronic kidney disease

Showing 8 posts of 8 posts found.

FDA approves Eli Lilly and Boehringer Ingelheim’s Jardiance for chronic kidney disease treatment

September 25, 2023
Medical Communications Boehringer Ingelheim, Eli Lilly, FDA, Nephrology, chronic kidney disease

Eli Lilly and Boehringer Ingelheim have announced that the US Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10mg …

News

NICE recommends Kapruvia for treatment of moderate-to-severe CKD-associated pruritus

May 18, 2023
Medical Communications Kapruvia, NICE, Nephrology, chronic kidney disease, pruritus

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics have announced that the National Institute for Health and Care …

News

Bayer’s cardiovascular drug shows impressive Phase III results

May 11, 2021
Manufacturing and Production Bayer, chronic kidney disease, pharma, pharma news, type 2 diabetes

Bayer’s finerenone drug has been shown to significantly reduce cardiovascular death or other cardiovascular events in patients with chronic kidney …

News
Evotec building

Evotec and Chinook to partner on new kidney disease treatments

March 1, 2021
Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease

Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …

News
janssen_latest_logo_on_sign

Janssen’s Invokana combo smashes primary and secondary endpoints in chronic kidney disease

April 16, 2019
Manufacturing and Production, Research and Development Janssen, cardiovascular, chronic kidney disease, diabetes, invokana, pharma

Janssen has unveiled promising new Phase 3 for its sodium-glucose transport (SGLT) protein-2 inhibitor Invokana (canagliflozin), showing that the therapy …

News
astrazeneca-sign

China becomes first country to approve roxadustat in chronic kidney disease

December 19, 2018
Research and Development, Sales and Marketing AstraZeneca, China, chronic kidney disease, pharma

AstraZeneca has announced that its partner Fibrogen has secured the first national approval for its hypoxia-inducible factor prolyl hydroxylase inhibitor …

News

Astellas’ chronic kidney drug shows superiority at Phase 3

September 20, 2018
Research and Development Astellas, chronic kidney disease, pharma, roxadustat

Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …

News
keryx_biopharma

Keryx Biopharmaceuticals announces positive Phase III study results for anaemia treatment

March 30, 2016
Research and Development CKD, anaemia, chronic kidney disease, clinical trial, dialysis, keryx, keryx biopharmaceuticals, kidney, phase 3, phase III

Keryx Biopharmaceuticals (NASDAQ: KERX) has announced positive top-line results for its Phase III study of ferric citrate for the treatment …

News

Latest content

Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement

April 25, 2024

Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment

April 25, 2024

Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals

April 24, 2024

GSK’s Jemperli accepted for FDA review for endometrial cancer treatment

April 24, 2024

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024